Document is current
Any future updates will be listed below
-
Authors
Cohen, Shachar
Shamai, Gil
Sabo, Edmond
Cretu, Alexandra
Barshack, Iris
Goldman, Tal
Bar-Sela, Gil
Pearson, Alexander T.
Huo, Dezheng
Howard, Frederick M.
Kimmel, Ron
Mayer, Chen
-
Funding
Funding for this research was provided by:
Israel Innovation Authority (69997)
Israel Innovation Authority (69997)
Israel Precision Medicine Partnership program (3864/21)
Israel Precision Medicine Partnership program (3864/21)
Zimin Institute for Artificial Intelligence Solutions in Healthcare
- License Information
-
More Information
Article History
Received: 20 July 2025
Accepted: 20 March 2026
First Online: 11 May 2026
Competing interests
: Howard reported receiving personal fees from Novartis AG and Leica Biosystems outside the submitted work. Alexander T. Pearson reports personal fees from the Prelude Therapeutics Advisory Board, Elevar Advisory Board, AbbVie consulting, Ayala Advisory Board, ThermoFisher Advisory Board, Break Through Cancer Scientific Advisory Board, Merck research funds, Kura Oncology research funds, and EMD Serono research funds. The other authors do not have a competing interest.
